One case of sequential delayed-to-immediate hypersensitivity reaction caused by sacituzumab tirumotecan for injection

doi:10.19803/j.1672-8629.20250854

Abstract

Abstract: Objective To analyze one case of sequential hypersensitivity reactions (HSRs) caused by sacituzumab tirumotecan for injection (sac-TMT) and provide a reference for safe clinical use. Methods One case of sequential HSRs in a patient with advanced breast cancer treated with sac-TMT was analyzed. Clinical manifestations, laboratory findings, and treatment regimens were analyzed with reference to literature. Results Delayed rash, pruritus, and fever occurred 4 days after the first dose, which was consistent with type Ⅳ HSR. During the second infusion, anaphylactic shock (typeⅠHSR) occurred 13 minutes after initiation and was classified as Brown grade 3. Total immunoglobulin E and interleukin-6 levels were elevated. Causality was determined as “probable”. After drug withdrawal and emergency treatment, the patient recovered. Sac-TMT was permanently discontinued. Conclusion Sac-TMT can induce sequential HSRs progressing from typeⅣ to typeⅠupon re-exposure, suggesting immunogenicity risks. For patients with risk factors for HSRs or a history of HSRs, comprehensive pre-treatment assessment and emergency preparedness are recommended in accordance with clinical guidelines and prescribing information.

Key words: Sacituzumab Tirumotecan for Injection, TypeⅣ Hypersensitivity Reaction, TypeⅠHypersensitivity Reaction, Sequential Reaction, Adverse Drug Reaction

CLC Number:

Xie Huali, Guan Bixi, Zhuo Yubo, He Jieli, Chen Zhe. One case of sequential delayed-to-immediate hypersensitivity reaction caused by sacituzumab tirumotecan for injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 938-940.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250854

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I8/938

References

[1] Wang R, Hu B, Pan Z, et al.Antibody-drug conjugates (ADCs): current and future biopharmaceuticals[J]. J Hematol Oncol, 2025, 18(1): 51.
[2] Killock D.Sacituzumab tirumotecan improves OS in mTNBC[J]. Nat Rev Clin Oncol, 2025, 22(6): 382.
[3] Fang W, Li X, Wang Q, et al.Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial[J]. BMJ, 2025, 389: e085680.
[4] Hong S, Wang Q, Cheng Y, et al.First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial[J]. Nat Med, 2025, 31(11): 3654-3661.
[5] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sacituzumab tirumotecan package insert, S20240052[EB/OL]. (2025-03-25)[2025-11-24]. https://db.yaozh.com/instruct/3720831340723584.html.
[6] Marwa K, Goldin J, Kondamudi N P.TypeⅣ hypersensitivity reaction[M/OL]. Treasure Island: Statpear Publishing, 2025. https://www.ncbi.nlm.nih.gov/books/NBK562228/.
[7] Isabwe G A C, Garcia Neuer M, De Las Vecillas Sanchez L, et al. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes[J]. J Allergy Clin Immunol, 2018, 142(1): 159-170.
[8] Center for Drug Reevaluation, National Medical Products Administration. Monitoring and Reporting/Drug GVP Guideline(监测与报告/药品GVP指南)[M]. Beijing: China Medical Science and Technology Press, 2022.
[9] Naranjo C A, Busto U, Sellers E M, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[10] Chow T G, Franzblau L E, Khan D A.Adverse reactions to biologic medications used in allergy and immunology diseases[J]. Curr Allergy Asthma Rep, 2022, 22(12): 195-207.
[11] Jeimy S, Wong T, Ben-Shoshan M, et al.Drug allergy[J]. Allergy Asthma Clin Immunol, 2025, 20(3): 78.
[12] Macy E, Trautmann A, Chiriac A M, et al.Advances in the understanding of drug hypersensitivity: 2012 through 2022[J]. J Allergy Clin Immunol Pract, 2023, 11(1): 80-91.
[13] Gelis S, Verdesoto J T, Pascal M, et al.Hypersensitivity reactions to monoclonal antibodies: new approaches[J]. Curr Treat Options Allergy, 2022, 9: 394-408.
[14] Davila M L, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Sci Transl Med, 2014, 6(224): 224ra25.
[15] Cardona V, Ansotegui I J, Ebisawa M, et al.World allergy organization anaphylaxis guidance 2020[J]. World Allergy Organ J, 2020, 13(10): 100472.
[16] Vega A, Jimenez-Rodriguez T W, Barranco R, et al. Hypersensitivity reactions to cancer chemotherapy: practical recommendations of ARADyAL for diagnosis and desensitization[J]. J Investig Allergol Clin Immunol, 2021, 31(5): 364-384.
[17] Aziz Kilany L A, Aboulwafa M M, Zedan H H. Therapeutic monoclonal antibodies: future prospectives[J]. J Cancer Immunol, 2021, 3(4): 177-182.
[18] Shapiro M A.Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer[J]. Front Oncol, 2024, 14: 1379738.
[19] Santos R B, Galvao V R.Monoclonal antibodies hypersensitivity: preva-lence and management[J]. Immunol Allergy Clin North Am, 2017, 37(4): 695-711.
[20] Mirakian R, Ewan P W, Durham S R, et al.BSACI guidelines for the management of drug allergy[J]. Clin Exp Allergy, 2009, 39(1): 43-61.
[21] Chung C H.Managing premedications and the risk for reactions to infusional monoclonal antibody therapy[J]. Oncologist, 2008, 13(6): 725-732.